Related Experiment Video
Updated: Dec 13, 2025
Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs
Published on: December 24, 2015
Use of multiple potency assays to evaluate human mesenchymal stromal cells
Barbara A Christy1, Maryanne C Herzig, Christopher P Delavan
1From the Blood and Coagulation Research Department (B.A.C., M.C.H., C.P.D., I.A., C.C., C.S., S.L., L.G., K.J., R.M., A.P.C., J.A.B.), US Army Institute of Surgical Research, JBSA Fort Sam Houston, Houston; Department of Molecular Medicine (B.A.C.), UT Health San Antonio; Joint Interdisciplinary Program in Biomedical Engineering Program (A.P.C., J.A.B.), UT San Antonio and UT Health San Antonio; Department of Surgery (A.P.C.), UT Health San Antonio, San Antonio; and Institute of Biomedical Studies (J.A.B.), Baylor University, Waco, Texas.
Background:
There is broad interest in the use of cell therapies and cell products for treatment of a variety of diseases and problems. Of interest to the military, cellular therapies have the potential to confer tremendous benefit for treatment of both acute and chronic injuries. Although many different cell therapy products are currently under investigation, mesenchymal stromal cells (MSCs) are good candidates, based on their ability to respond to inflammation, limit vascular permeability, and modulate immune responses to injury. Although a large number of clinical trials utilize MSCs or their products, there is no firm consensus defining the characteristics and activities of a good MSC product. Here, we test multiple human MSCs in several assays designed to test potency, to determine if functionally relevant differences between MSCs can be defined using in vitro assays, allowing identification of superior MSC products for preclinical or clinical testing.
Methods:
Human MSCs derived from several tissue sources (adipose, bone marrow, umbilical cord) were evaluated for their ability to respond to inflammatory signaling by upregulating indoleamine-2,3-dioxygenase and TSG6, suppress lymphocyte proliferation, alter the polarization of macrophages, and affect tube formation by endothelial cells.
Results:
All MSCs tested displayed activity in the functional assays utilized, but differences in potency were observed in each assay.
Conclusion:
The indoleamine-2,3-dioxygenase enzyme activity assay represents a simple way to screen multiple samples. The mixed lymphocyte reaction and monocyte assays used to test interactions between MSCs and immune cells are more involved but give direct information on immunomodulation potential. The endothelial cell tube formation assay is relatively simple to perform but a large number of images must be generated and analyzed. However, it tests a functional activity other than immunomodulation and, therefore, adds another facet to MSC evaluation.
